期刊档案
European Medical Journal Rheumatology
ISSN 2056-6395 · European Medical Journal · United Kingdom
European Medical Journal Rheumatology 钻石开放获取(无 APC),免版面费,投稿社区反馈审稿约 22 周,2025 年发文 18 篇。
研究范围
研究范围与定位
European Medical Journal Rheumatology 由 European Medical Journal 出版。按 OpenAlex 近年发文统计,该刊主要发表 Rheumatoid Arthritis Research and Therapies、Systemic Lupus Erythematosus Research、Spondyloarthritis Studies and Treatments 等主题的论文,这 3 个主题约占 40.3%,主导子领域为 Rheumatology。(根据 OpenAlex 主题统计与中科院分区数据生成)
EMJ Rheumatology is an open access, peer-reviewed eJournal committed to publishing the highest quality medical research concerning all aspects rheumatic function and disease to help advance the development of this field. The journal is published annually, six weeks after the European Alliance of Associations for Rheumatology (EULAR) Congress, and features highlights from this congress, alongside interviews with experts in the field, reviews of abstracts presented at the congress, as well as in-depth features on congress sessions. Additionally, this journal covers advances within the clinical and pharmaceutical arenas by publishing sponsored content from congress symposia, which is of high educational value for healthcare professionals. This undergoes rigorous quality control checks by independent experts and the in-house editorial team. EMJ Rheumatology also publishes peer-reviewed research papers, review articles, and case reports in the field. In addition, the journal welcomes the submission of features and opinion pieces intended to create a discussion around key topics in the field and broaden readers’ professional interests. EMJ Rheumatology is managed by a dedicated editorial team that adheres to a rigorous double-blind peer-review process, maintains high standards of copy editing, and ensures timely publication. EMJ Rheumatology endeavours to increase knowledge, stimulate discussion, and contribute to a better understanding of rheumatic diseases. Our focus is on research that is relevant to all healthcare professionals in the field. We do not publish veterinary science papers or laboratory studies not linked to patient outcomes. We have a particular interest in topical studies that advance research and inform of coming trends affecting clinical practice in rheumatology. Topics include (but are not limited to): Inflammatory arthritis Osteoarthritis Paediatric and adolescent rheumatological disease Vasculitis Connective tissue diseases Auto-inflammatory disorders Guidelines in rheumatology practice Spondyloarthropathies Immunodeficiency states (primary and secondary) Sjögren’s syndrome Treatment issues of rheumatic disease Rheumatic musculoskeletal disease Immunity in rheumatic diseases Rheumatic arthritis Epidemiology Bone diseases Systemic sclerosis Myositis Orphan/rare diseases Biosimilars
摘自期刊官网 Aims & Scope
主编 Ian C. Chikanza出版商官网
编委会国家分布:未见中国大陆编委;主要国家 英国 2、土耳其 2、美国 1、德国 1、西班牙 1(共 11 位编委标注了国家) 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计,占比为近似值
- Rheumatoid Arthritis Research and TherapiesMedicine22.8%
- Systemic Lupus Erythematosus ResearchMedicine8.8%
- Spondyloarthritis Studies and TreatmentsMedicine8.8%
- Musculoskeletal Disorders and RehabilitationMedicine6.7%
- Autoimmune and Inflammatory Disorders ResearchMedicine6.4%
- Systemic Sclerosis and Related DiseasesMedicine4.7%
- Musculoskeletal pain and rehabilitationMedicine4.4%
- Bone health and osteoporosis researchMedicine3.5%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表( 2025年3月升级版)未收录
该期刊未被此版本分区表收录。
《新锐期刊分区表》( 2026年3月发布)未收录
该期刊未被此版本分区表收录。
期刊分区表( 2023年12月旧的升级版)未收录
该期刊未被此版本分区表收录。
数据库收录
DOAJLetPub
国际期刊预警名单:各版本均未列入LetPub
期刊官网自述收录
Google Scholar出版商官网
期刊官网列出的收录清单,未与各数据库逐一核对;Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- h-index
- 8OpenAlex ·
- i10-index
- 3OpenAlex ·
- 两年平均被引
- 0.11OpenAlex ·
- Gold OA 文章占比
- 0%LetPub ·
逐年发文量 OpenAlex 统计 · 累计 178 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 29 | 29 | 22 |
| 2025 | 18 | 18 | 23 |
| 2024 | 24 | 24 | 29 |
| 2023 | 17 | 17 | 29 |
| 2022 | 7 | 7 | 42 |
| 2021 | 8 | 8 | 32 |
不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
- 平均审稿速度(社区反馈)
- 22 WeeksLetPub ·
- 投稿到发表(期刊自报)
- 约 22 周DOAJ ·
- 评审方式
- 双盲同行评审DOAJ
社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
所有文章开放获取,且不向作者收取文章处理费。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | 无文章处理费 | 无 | CC BY-NC | |
| LetPub | 无文章处理费 | 无 | — | |
| 出版商官网 | 无文章处理费 | — | — |
- APC 费用说明 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。
投稿要求
文章类型与投稿政策(官网)
投稿准备要点2 项,摘自作者指南
- 关键词
- 3–10 个
- 投稿信(Cover letter)
- 必须提供
接收的文章类型13 种
- case reportOriginal research (abstract: structured, ≤250 words; main text: <3,000 words +/-10%; combined maximum of 3 tables or figures; maximum 60 references +/-10%). Ori…未说明篇幅
- case reportsCase reports (abstract: unstructured, ≤250 words; main text: <3,000 words +/-10%; maximum of 3 tables or figures; maximum 60 references +/-10%).未说明篇幅
- editorialThe Editorial Staff will evaluate disclosed conflicts to determine if they are significant enough to preclude publication or require additional scrutiny. Review…未说明篇幅
- feature articlesArticles accepted for publication within the eJournals and website include original research, review articles, case reports, and feature articles such as opinio…未说明篇幅
- literature reviewOriginal research (abstract: structured, ≤250 words; main text: <3,000 words +/-10%; combined maximum of 3 tables or figures; maximum 60 references +/-10%). Ori…未说明篇幅
- meta-analysisOriginal research (abstract: structured, ≤250 words; main text: <3,000 words +/-10%; combined maximum of 3 tables or figures; maximum 60 references +/-10%). Ori…未说明篇幅
- narrative reviewOriginal research (abstract: structured, ≤250 words; main text: <3,000 words +/-10%; combined maximum of 3 tables or figures; maximum 60 references +/-10%). Ori…未说明篇幅
- original researchOriginal research (abstract: structured, ≤250 words; main text: <3,000 words +/-10%; combined maximum of 3 tables or figures; maximum 60 references +/-10%). Ori…未说明篇幅
- perspectiveOriginal research (abstract: structured, ≤250 words; main text: <3,000 words +/-10%; combined maximum of 3 tables or figures; maximum 60 references +/-10%). Ori…未说明篇幅
- reviewOriginal research (abstract: structured, ≤250 words; main text: <3,000 words +/-10%; combined maximum of 3 tables or figures; maximum 60 references +/-10%). Ori…未说明篇幅
- review articleOriginal research (abstract: structured, ≤250 words; main text: <3,000 words +/-10%; combined maximum of 3 tables or figures; maximum 60 references +/-10%). Ori…未说明篇幅
- review articlesReview articles (abstract: unstructured [unless a systematic review], ≤250 words; main text: <3,000 words +/-10%; maximum of 3 tables or figures; maximum 60 ref…未说明篇幅
- systematic reviewOriginal research (abstract: structured, ≤250 words; main text: <3,000 words +/-10%; combined maximum of 3 tables or figures; maximum 60 references +/-10%). Ori…未说明篇幅
官网政策摘录作者资格、利益冲突、出版伦理、许可与版权、开放获取、同行评审、查重
- 作者资格 Authorship
署名意味着对已发表工作承担责任与问责,并为研究者的贡献提供署名。署名可授予对研究的分析与解释有贡献、但未必参与研究构思与设计的个人。每位作者的贡献与责任都应写明。作者可致谢其他帮助过研究过程但未达到署名贡献要求的人(如某位教授)。 模型中文摘要
Authorship implies responsibility and accountability for published work as well as providing credit for a researcher’s contributions to a study. Assignment of authorship is to individuals who have contributed to the analysis and interpretation of a study but who may not have contributed to its conception and design. The contribution and responsibility of every author should be included. Authors ma…
原文 ↗出版商官网 ·- 利益冲突 Disclosure and Conflicts of Interest
当对稿件的职业判断可能受次要利益(如经济利益)影响时,即存在利益冲突。例如,需披露作者(或其直系亲属)受雇、签约、提供服务或以其他方式合作的任何制药、生物制品、医疗器械及诊断公司的名称(及关系)。 模型中文摘要
A conflict of interest can be said to exist when professional judgement concerning the manuscript may be influenced by a secondary interest (e.g., financial gain). For example, this would include disclosing the names of (and relationship with) any pharmaceutical, biologics, medical device, and diagnostic companies for which an author (or one of their close family members) is employed, contracted f…
原文 ↗出版商官网 ·- 出版伦理 Ethical Approval
开展医学研究的所有作者应遵循《赫尔辛基宣言》。研究类文章:作者应能应要求提交机构审查委员会或伦理委员会批准该研究的声明。作者还应尽一切努力保护患者隐私与匿名;仅在关键且不可避免时才可包含可能识别身份的信息。 模型中文摘要
We expect that all authors conducting medical research follow the Declaration of Helsinki, which can be viewed here: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Research articles: Authors should be able to submit, upon request, a statement from their institutional review board or ethics committee indicating approv…
原文 ↗出版商官网 ·- 许可与版权 Copyright
版权是授予作品创作者的法定权利,适用于文学、戏剧、音乐、艺术、录音、影片、广播及有线节目和出版版本的版式编排等作品。对作者而言,通常涉及图表或照片。若要使用非本人创作的图像,很可能涉及版权;未经版权持有人同意,复制、改编、出租出借或向公众提供作品副本、公开表演或播放作品均属违法。 模型中文摘要
Copyright is the legal right given to the creator of a piece of work. The types of work to which copyright applies include literary, dramatic, musical, artistic, sound recording, films, broadcasts and cable programmes, and typographical arrangement of published editions. Usually for authors copyrighted material will be figures, tables or photos. If you want to include an image in your manuscript t…
原文 ↗出版商官网 ·- 开放获取 Open Access
本刊为开放获取期刊,采用知识共享署名-非商业性使用4.0(CC BY-NC 4.0)许可。允许用户以任何媒介或格式复制并再分发材料,以及混合、转换和在此基础上创作;条件是须给予适当署名、提供许可链接并注明是否作了修改,且不得暗示许可方认可使用者或其使用方式;不得将材料用于商业目的。 模型中文摘要
We are an open-access journal in accordance with the Creative Commons Attribution-Non Commercial 4.0 (CC BY-NC 4.0)< license. This permits users to: Share – Copy and redistribute the material in any medium or format. Adapt – Remix, transform, and build upon the material. Under the following terms: Attribution – You must give appropriate credit, provide a link to the license, and indicate if change…
原文 ↗出版商官网 ·- 同行评审 Peer Review Process
所有投稿先由编辑团队初审,质量不高、不符合指南或超出期刊范围的稿件可在同行评审前被拒,以便作者快速获得决定。通过初审的稿件将送至少两名独立审稿人进行双盲同行评审。稿件将根据同行评审反馈、作者修改的配合程度及编辑的最终选择决定是否发表。 模型中文摘要
All submissions are initially reviewed by the Editorial team. At this stage, papers may be rejected before peer review if we feel that they are not of high enough quality, do not follow our guidelines, or are not within the scope of the journal. This ensures that authors are given a quick decision if their paper is unsuitable. Papers that pass the initial review process will be sent out for peer r…
原文 ↗出版商官网 ·- 查重 Policy on Plagiarism
向EMJ投稿即表示稿件为原创、未发表且未同时投给其他刊物。数据造假或捏造、抄袭(包括未恰当引用而重复发表作者本人作品)及盗用他人作品均属不可接受。经Kriyadocs投稿平台提交的稿件将进行抄袭筛查,相关学术不端将按COPE指南严肃处理。 模型中文摘要
By submitting your manuscript to the EMJ it is understood that it is an original manuscript, is unpublished work and is not under consideration elsewhere. Falsification or fabrication of data, plagiarism, including duplicate publication of the authors’ own work without proper citation, and misappropriation of the work are all unacceptable practices. All manuscripts submitted to EMJ via the Kriyado…
原文 ↗出版商官网 ·
摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。
基本信息
出版信息与官方入口
- 出版商
- European Medical Journal
- 出版国家或地区
- United Kingdom
- 出版语言
- English
- ISSN
- 2056-6395
- 官方链接
- 期刊主页 ↗DOAJ
- 作者指南 ↗DOAJ
- Aims & Scope ↗DOAJ
- APC 费用说明 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗DOAJ
- 编委会 ↗DOAJ
常见问题
关于 European Medical Journal Rheumatology 的常见问题
European Medical Journal Rheumatology 的审稿周期多长?
投稿社区反馈的平均审稿速度为约 22 周。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。
European Medical Journal Rheumatology 的投稿格式要求是什么?
据期刊作者指南:关键词:3–10 个;投稿信:必须提供。以上由模型从作者指南提取并逐项与原文核对,投稿前请以官网最新版本为准。
European Medical Journal Rheumatology 的编委会里有中国学者吗?
期刊官网编委会页面上标注了国家的 11 位编委中,没有中国大陆学者;人数最多的国家是 英国(2 位)、土耳其(2 位)、美国(1 位)。统计按编委会页面列出的机构国家计,仅供参考。
European Medical Journal Rheumatology 被哪些数据库收录?
据 LetPub 与 DOAJ 记录,European Medical Journal Rheumatology 被 DOAJ 收录。
European Medical Journal Rheumatology 是开放获取期刊吗?版面费多少?
European Medical Journal Rheumatology 为钻石开放获取(无 APC)。不收取文章处理费。
来源与更新
本页事实来自 LetPub、OpenAlex、DOAJ、出版商官网;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-25 归档)。最近更新:。